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ABSTRACT Plasma prorenin and active renin were mea-
sured before and after human chorionic gonadotropin (hCG)
administration in two groups of patients undergoing ovarian
stimulation for 4-6 days with follicle-stimulating hormone
alone or in combination with luteinizing hormone, for in vitro
fertilization. Baseline total plasma renin (prorenin plus active
renin; n = 12) averaged 25 ± 8 ng/ml per hr (mean ± SD).
Total renin did not change during ovarian stimulation but it
increased to 46 ± 16 ng/ml per hr (P < 0.05) 1 or 2 days later,
just before hCG administration. Thirty-six hours after hCG
administration, just before laparoscopy and egg retrieval, total
renin was 123 ± 97 ng/ml per hr; a peak of 182 ± 143 ng/ml
per hr occurred 2-6 days later-i.e., during the luteal phase of
the menstrual cycle. In eight of the patients who did not
conceive, total renin returned to baseline 14 days after hCG
administration. In four who conceived, a nadir was reached (57
+ 13 ng/ml per hr) 8-12 days after hCG administration and
then total renin increased again as the plasma .hCG measure-
ment began to rise. By day 16 it averaged 225 ± 157 ng/ml per
hr. In a second group of five patients active renin and prorenin
were measured separately. Active renin comprised <20% of
the total renin at all times. It was unchanged until day 4 after
hCG administration and then increased significantly only when
plasma progesterone was high. Thus, the initial response to
hCG was entirely due to an increase in prorenin. A highly
significant correlation was observed between the number of
follicles and the total renin increases on the day of aspiration
(r = 0.93, P < 0.001) and at the peak (r = 0.89, P < 0.001).
After hCG administration, a temporal relationship was ob-
served between the rise in total renin and plasma estradiol and
progesterone levels. These results demonstrate that plasma
prorenin increases markedly after administration of hCG and
that the rise is directly related to the number of ovarian follicles
and to plasma estrogen and progesterone levels. The findings
suggest that prorenin is produced by the mature ovarian follicle
and by the corpus luteum in response to gonadotropin stimu-
lation.
The renin-angiotensin system plays a key role in blood
pressure, fluid and electrolyte homeostasis through the
vasoconstrictor action of angiotensin II, and the stimulation
of aldosterone biosynthesis by the adrenal zona glomerulosa
cells (1). Active renin is synthesized by and secreted from the
kidney. Prorenin, its enzymatically inactive precursor, cir-
culates at higher concentrations than active renin (2) and is
also mostly derived from the kidneys. Nonetheless, it persists
at low levels in the blood of chronically nephrectomized
females and males (3-5). Prorenin is also synthesized by the
placenta (6-8) and is markedly increased in the plasma of
pregnant women (9-12). However, the early pregnancy-
related rise in plasma prorenin is apparently not due to
placental secretion since it did not occur in a patient with
ovarian failure (13).
Recent evidence suggests that prorenin (13-18) and the
renin-angiotensin system (14, 19, 20) may be linked to ovarian
physiology. Mature human ovarian follicles contain prorenin
in high concentrations (14, 18); only 1% is enzymatically
active (14). Plasma prorenin, but not active renin, increases
at midmenstrual cycle just after the luteinizing hormone (LH)
surge (15, 16) and a second but lower rise in prorenin,
together with active renin, occurs later (15) when progester-
one is high.
Ovarian hyperstimulation with gonadotropins results in the
development of multiple follicles and consequently many
corpora lutea. Preliminary studies suggest that such patients
have a marked rise in prorenin in response to human
chorionic gonadotropin (hCG) (13, 14, 17). We therefore
examined the relationship of the hCG-induced increase in
prorenin to the number of follicles induced by ovarian
stimulation and to the changes in plasma estradiol and
progesterone that occurred in patients undergoing follicular
aspiration for in vitro fertilization and embryo transfer.
METHODS
Patients. Two groups of patients undergoing ovarian stim-
ulation for in vitro fertilization and embryo transfer were
studied. Group A consisted of 12 patients in whom serum
samples for routine hormonal measurements were retrospec-
tively analyzed. We selected patients in whom both ovaries
had been completely available for follicular aspiration. Ten
patients had irreparable tubal disease and in 2 patients the
cause of infertility was unknown. Ovarian stimulation was
accomplished as reported (21-24). Seven patients were treat-
ed with "pure" follicle-stimulating hormone (FSH) [Metro-
din, Serono Laboratories (Randolph, MA), containing 75
international units (IU) of human urinary FSH and <1 IU of
LH in each ampule] and 5 patients were treated with a
combination of "pure" FSH and human menopausal
gonadotropin (HMG) (Pergonal, Serono Laboratories, con-
taining 75 IU of FSH and 75 IU of LH). In the FSH-only
protocol, four ampules of FSH were injected on days 3 and
4 of the menstrual cycle; this was followed by injection of two
ampules of FSH on subsequent days. In the FSH/HMG
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protocol, two ampules of FSH and two ampules of HMG
were injected on days 3 and 4 of the cycle; this was followed
by injection of two ampules of HMG on subsequent days.
After 5-7 days of treatment, hCG (10,000 IU) was injected as
a surrogate LH surge (defined as day 0). hCG was adminis-
tered 28-52 hr following the last injection of gonadotropins
(FSH or HMG). Follicles were aspirated by laparoscopy
under general anesthesia about 36 hr later (day 2). All visible
follicles were aspirated and the maturation of the oocytes and
the granulosa cells from each follicle was determined (24). In
vitro fertilization of the oocytes and embryo culture were
accomplished as reported (24). Starting on day 3, patients
were treated with intramuscular injection of progesterone, 25
mg/day, and embryos were transferred to the uterus on day
4.
Group B consisted of five patients studied prospectively in
whom plasma samples instead of serum samples were col-
lected so that changes in active renin could be examined.
Four patients had irreparable tubal disease and in one patient
the cause of infertility was related to male factor. Three
patients were treated with FSH only and two patients were
treated with a combination of FSH/HMG. Protocols similar
to those described for patients in group A were employed. At
laparoscopy both ovaries were found to be completely
available in three patients. However, in two patients only
about 70% of the ovarian surface was available for aspiration.
Blood Collection and Processing. Serum samples (group A)
or plasma samples (group B) were collected daily at
0800-0900 a.m. until day 2 and on alternate days thereafter.
On the day of laparoscopy blood samples were withdrawn 15
min before the induction of anesthesia. The serum samples
from group A were frozen and thawed several times for
routine hormonal measurements, which caused cryoactiva-
tion of prorenin and falsely high active renin values (2). For
this reason only total renin values are reported in group A
patients. For group B, blood was collected into K2EDTA
Vacutainers and maintained at room temperature until the
plasma was separated. Active renin was usually measured
after only one freezing and thawing cycle; however, samples
that were collected 6 or more days following hCG adminis-
tration (see below) were exposed to two freezing and thawing
cycles. (From day 6, samples were mailed by the patients to














Hormonal Measurements. Prorenin in serum or plasma was
converted to active renin by limited proteolysis with Seph-
arose-bound trypsin, as described (15). Active renin was
measured by enzymatic assay utilizing endogenous plasma
renin substrate (25). For serum samples, 3 mM EDTA was
added before the enzymatic assay to inhibit angiotensinases
and converting enzyme. The angiotensin I formed during the
enzymatic assay was measured by RIA (25). Plasma prorenin
was calculated as the difference between the endogenous
active renin and the total renin measured after trypsin
activation. Results are expressed as the rate of angiotensin I
formation (ng/ml per hr). Serum estradiol and progesterone
were assayed using a commercially available RIA kit (Pantex,
Santa Barbara, CA), as reported (22).
Statistical Analysis. The significance ofchanges in hormone
levels during the cycle was calculated by using the paired
Student's t test with Bonferroni's correction for multiple
measurements (26). Correlations between total renin and
number of follicles were determined by regression analysis.
P < 0.05 was considered to be significant.
RESULTS
Group A. At laparoscopy 10.6 ± 5.6 follicles (mean ± SD;
range, 3-20) were aspirated and mature granulosa cells were
detected in 88.6% ± 10.1% (range, 66.6-100%) of the
aspirated follicles (24).
Total renin levels. The total renin results from two of these
patients were reported in a short preliminary communication
(13). Baseline total serum renin (day 3 of menstrual cycle)
was 25 ± 8 ng/ml per hr (mean ± SD); it remained relatively
stable during the administration of FSH and FSH/LH in the
follicular phase (Fig. 1). A small but consistent increase was
observed on the day of hCG injection (day 0) before hCG was
administered (P < 0.05) (Fig. 1 and Table 1). Following hCG
injection a marked and sustained increase in total renin was
observed. Just before follicular aspiration (day 2) it had risen
to 6.4-fold baseline (range, 1.7-15.3) and it further increased
slightly to reach a peak of 9.0-fold baseline (range, 2.4-22.5),
either on day 4 (n = 5), day 6 (n = 6), or day 8 (n = 1). (See
Fig. 2 for an illustration of the spectrum of responses.) Thus,
the highest level of total renin occurred after follicle aspira-
























FIG. 1. Serum total renin, estradiol, and progesterone changes (mean ± SEM) in 12 patients undergoing ovarian stimulation with
gonadotropins and hCG. Baseline is the third day after the beginning of menstruation. hCG was administered on day 0 and ovarian follicles were
aspirated on day 2 after blood sampling. Total serum renin was significantly higher than baseline on day 0 (P < 0.05) and was almost back to
baseline on day 14 in 8 patients who did not conceive. In 4 pregnant women total renin increased again after day 10. Estradiol was above baseline
(P < 0.05 or greater) from day -4 until day 12. Progesterone was above baseline on day 1 and thereafter. The shaded area represents the estimated
level of serum progesterone (based on the level of progesterone on day 14 in the nonpregnant patients) caused by the administration ofexogenous
progesterone (25 mg/day), which was given from day 3 until day 14. The serum estradiol and progesterone values after day 10 are from the 8
nonpregnant women.
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Table 1. Total serum renin and progesterone before (-) and
after (+) hCG injection
Total renin, Progesterone,
Day ng/ml per hr ng/ml
Baseline* 25 ± 8 0.7 ± 0.3
-1 38 ± 12 0.8 ± 0.3
0 46 ± 16t 1.3 ± 0.9
+1 63 ± 23t 3.8 ± 0.3t
+2 148 ± 97t 5.1 ± 3.6t
Data are expressed as mean ± SD (n = 12).
*Baseline = day 3 of the menstrual cycle.
tP < 0.05 compared to baseline levels.
patients who did not conceive, total renin had fallen to 132%
of baseline level on day 14 and they had undetectable hCG
levels. In the four women who conceived, total renin reached
a nadir on days 8-12 (57 ± 13 ng/ml per hr) and then
increased to 225 ± 157 ng/ml per hr on day 16 (Fig. 1), when
hCG was 424 ± 293 mIU/ml.
Magnitude of increase in total renin in relation to the
number of ovarian follicles. Analysis of the relationships
between the increase in total serum renin and the number of
aspirated follicles on day 2 disclosed a highly significant
correlation (r = 0.93, P < 0.001, Fig. 3A). A somewhat
weaker correlation (r = 0.73, P < 0.01) was observed on day
1 (8-12 hr after hCG injection). Total renin was also higher
than baseline on day 0 but the relationship to the number of
follicles was not significant (r = 0.32).
The maximum increase in total renin after hCG adminis-
tration occurred during the luteal phase and the peak value in
each subject was highly related to the number of follicles (r
= 0.89, P < 0.001, Fig. 3B). Fig. 2 illustrates the changes in
serum total renin in representative individual subjects with
low, intermediate, or high numbers of follicles. For compar-
ison, the levels of total plasma renin throughout a repre-
sentative natural cycle are also illustrated (16).
Temporal relationship between blood levels of total renin,
estradiol, and progesterone. Estradiol increased during the
follicular phase during the period of ovarian stimulation by
gonadotropins; estradiol fell after hCG injection and fell
further after follicular aspiration, but rose again during the
luteal phase (Fig. 1). The number of follicles correlated with
plasma estradiol on day 0 (r = 0.84, P < 0.01), day 1 (r = 0.89,
P < 0.001), and day 2 (r = 0.87, P < 0.001) (Fig. 3C). Not
surprisingly, a significant correlation between estradiol and
total renin was also demonstrated (Fig. 3D). Baseline pro-
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FIG. 2. Total serum renin levels throughout the stimulated cycles
of three representative patients with different numbers of ovarian
follicles. Shown for comparison are the changes in total plasma renin
throughout a natural cycle (16) in which only one follicle usually
matures.
ng/ml; it increased slightly on day 0 (Fig. 1 and Table 1).
Following a peak of >80 ng/ml on day 8, progesterone fell to
about 20 ng/ml on days 12 and 14. The hormonal level on days
12 and 14 was largely due to the daily injection of exogenous
progesterone and so the corpora lutea were apparently
contributing an average of 60 ng of progesterone per ml at the
peak. Total serum renin disclosed a temporal relationship
with serum progesterone levels through the follicular and the
luteal phases and with estradiol levels during the luteal phase.
However, the rise and fall of both serum estradiol and
progesterone during the luteal phase were preceded by the
rise and fall of total serum renin (Fig. 1 and Table 1).
Group B. In this second prospectively studied group of
patients, 8.2 ± 2.2 (range, 6-11) follicles per patient were
aspirated and 73.2% ± 16.4% (range, 45.5-85.7%) were
classified as mature follicles.
The changes in plasma prorenin, active renin, and proges-
terone are shown in Fig. 4. Baseline plasma active renin was
1.9 ± 1.1 ng/ml per hr (mean ± SD); unlike plasma prorenin,
active renin remained unchanged until day 6 after hCG
administration. On day 6 and thereafter, active renin levels
increased significantly (P < 0.01), at a time when plasma
prorenin was falling and plasma progesterone was at peak
levels. Active renin comprised only 8% ± 2% of total renin
under baseline conditions and was 11% ± 6%, 4% ± 3%, 5%
± 1%, and 11% ± 4% on days 0, 2, 6, and 8, respectively. The
pattern of change in plasma prorenin resembled that of total
plasma renin in group A (Fig. 1). The lack ofa further increase
in plasma prorenin from day 2 to day 4 in this group may be
related to the fact that in two patients plasma samples from
day 4 were not available for analysis. These two patients had
the highest prorenin levels on day 2 (250 and 127 ng/ml per
hr).
DISCUSSION
The present results demonstrate that hCG administration
following ovarian hyperstimulation with gonadotropins re-
sults in marked and sustained increases in circulating
prorenin. The levels achieved are much higher than those that
occur normally during the spontaneous LH surge of a natural
cycle. As in natural cycles, active plasma renin was essen-
tially unchanged until the luteal phase. The height of the
circulating prorenin response to hCG was directly related to
the number of mature follicles detected at the time of
aspiration, suggesting that prorenin is produced and secreted
by the ovarian follicles. Furthermore, a temporal relationship
between plasma prorenin and corpus luteum steroidogenic
activity was also demonstrated.
Relationship of Prorenin Levels to the Number of Mature
Follicles. During the follicular phase of the menstrual cycle
only one follicle normally matures and ovulates, and plasma
prorenin increases an average of 90% after the LH surge for
about 2 days (16). In stimulated cycles there was a greater
response of prorenin, the magnitude of which was directly
related to the number of follicles. The highest prorenin levels
seen in nonpregnant women (586 ng/ml per hr, 21-fold
baseline) occurred in a patient who had 20 follicles. The
average increase in prorenin per follicle (46% on day 2 and
63% on day 6) was similar to that that occurs after the
spontaneous LH surge (16). This suggests that the high
plasma prorenin levels after ovarian stimulation are due to
the presence of multiple follicles and not to abnormally high
prorenin secretion by individual follicles. Any small follicles
that were not counted either contributed little to circulating
levels of prorenin or were proportional to the number of
mature follicles. The highly significant correlation between
the plasma prorenin concentration during the luteal phase and
the number offollicles suggests that prorenin was secreted by
the corpora lutea that were formed from the follicles.
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FIG. 3. (A) Relationship be-
tween the change in total serum
renin and the number of follicles
on day of ovarian follicle aspira-
tion (day 2). (B) Relationship
between the maximal change in
total serum renin in the luteal
phase and the number of ovarian
follicles. (C) Relationship be-
tween serum estradiol levels on
the day of aspiration (day 2) and
the number of follicles. (D) Re-
lationship between the change in
total serum renin and serum
estradiol levels on the day of
ovarian follicle aspiration (day
2).
Time Course of Prorenin and Active Renin Responses.
Plasma prorenin does not increase during natural menstrual
cycles before the LH surge (15, 16). In contrast, a small but
significant increase in prorenin was detected on day 0, before
the hCG injection, in the stimulated patients. This rise
occurred whether the patients had been stimulated with FSH
alone or with a combination of FSH/LH and was therefore
not due to the exogenously administered LH. A spontaneous
LH surge does not usually occur in hyperstimulated women
(27). Presumably, the growing follicle normally secretes small
amounts of prorenin, but the secretion of prorenin only
increases enough to be detectable when multiple follicles
develop.
In the natural menstrual cycle the peak of prorenin is
sustained for about 1 day after the LH surge (16). In contrast,
hCG injection in stimulated women caused a sustained
increase in prorenin that peaked on days 4-6 and did not
return to baseline until days 12-14. This prolonged response
is most probably related to the longer half-life of hCG (-'32
hr) compared to LH (':1 hr) (28). The sensitivity of the corpus
luteum to hCG is also reflected in the precipitous rise of
prorenin after day 12 in the pregnant women (present study
and ref. 13).
That the initial increase in prorenin after hCG administra-
tion is not associated with an increase in active renin has been
clearly demonstrated in this study. The prorenin rise after the
LH surge in the natural cycle is also not associated with a
significant rise in active renin (15, 16). However, both in
natural cycles (15, 29) and in this study, active renin in-
creased during the luteal phase when progesterone was high.
This response could be related to the natriuretic effect of
progesterone (29) and therefore be of renal origin (Fig. 4).
Alternatively, it may be the result of in vitro cryoactivation
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FIG. 4. Plasma prorenin, active renin, and progesterone levels (mean + SEM) throughout the cycle in five patients treated with gonadotropins
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were frozen and thawed twice and also delivered on dry ice
to Norfolk).
Temporal Relationship Between Prorenin and Ovarian Hor-
mones Level. Estradiol is the primary hormone secreted by
the granulosa cells of the preovulatory follicle (30-32).
Ovarian stimulation was associated with an augmented in-
crease in plasma estradiol during the follicular phase that
correlated with the number of follicles. A significant corre-
lation was observed between prorenin and estradiol levels on
days 1 and 2 following hCG injection. It is unclear whether
the level of each hormone is independently related to the
number of maturing follicles or whether this correlation
represents a cause and effect relationship. It is possible that
estradiol (or its androgen precursors) stimulates ovarian
prorenin biosynthesis. Alternatively, locally produced pro-
renin may affect estrogen levels by causing alterations in
thecal/interstitial androgen biosynthesis or metabolism.
The transition between preovulatory follicle and corpus
luteum entails a decline in follicular estrogen biosynthesis
and an increase in progesterone biosynthesis. Examination of
the pattern of prorenin and progesterone levels through the
stimulated cycle disclosed a striking temporal relationship
between the two hormones. The prorenin rise preceded the
increase in progesterone. The idea that ovarian prorenin may
be a mediator of the LH/hCG-induced transition between
preovulatory follicle and corpus luteum steroidogenic activ-
ity is attractive and deserves further study.
Angiotensin II affects intracellular calcium and phosphati-
dylinositol metabolism (33, 34). Therefore ovarian prorenin,
through angiotensin II action, may be involved in other
ovarian endocrine events. Putative actions of the ovarian
prorenin-renin-angiotensin system include control of ovarian
blood flow through its effect on vascular smooth muscle tone
(1) and the angiogenic property of angiotensin II (35).
The finding that changes in plasma prorenin are not
accompanied by significant changes in active renin has led to
speculation that prorenin is activated locally at its site of
action (36). That angiotensin II might be formed locally is
supported by the reports that extrarenal renin is found in the
same cells as the other components of the renin system (37,
38).
In summary, these results are consistent with the view that
ovarian prorenin is produced and secreted by the mature
follicle and by the corpus luteum in response to stimulation
by LH/hCG. Further studies to investigate the role of
prorenin in follicular development and corpus luteum func-
tion are needed. However, the results from the present study
suggest that ovarian prorenin may be related to ovarian
steroidogenic activity.
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